Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation : Phase II Trial SAKK19/09
ContributorsGautschi, Oliver; Mach, Nicolas; Rothschild, Sacha I.; Li, Qiyu; Stahel, Rolf A.; Zippelius, Alfred; Cathomas, Richard; Früh, Martin; Betticher, Daniel C.; Peters, Solange; Rauch, Daniel; Feilchenfeldt, Jonas; Bubendorf, Lukas; Savic, Spasenija; Jaggi, Rolf; Leibundgut, Elisabeth Oppliger; Largiadèr, Carlo; Brutsche, Martin; Pilop, Christiane; Stalder, Lukas; Pless, Miklos; Ochsenbein, Adrian F.; Swiss Group for Clinical Cancer Research
Published inClinical lung cancer, vol. 16, no. 5, p. 358-365
Publication date2015-09
Keywords
- Bevacizumab
- Chemotherapy
- Erlotinib
- Lung cancer
- Pemetrexed
Affiliation entities
Research groups
Citation (ISO format)
GAUTSCHI, Oliver et al. Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non–Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation : Phase II Trial SAKK19/09. In: Clinical lung cancer, 2015, vol. 16, n° 5, p. 358–365. doi: 10.1016/j.cllc.2015.02.007
Main files (1)
Article (Published version)
Identifiers
- PID : unige:175790
- DOI : 10.1016/j.cllc.2015.02.007
- PMID : 25843489
Additional URL for this publicationhttps://linkinghub.elsevier.com/retrieve/pii/S1525730415000601
Journal ISSN1525-7304
